CA2220517A1 - Aryl-imidazolines et aryl-imidazoles utiles en tant qu'agents agonistes adrenergiques alpha-2 n'entrainant pas d'effets secondaires cardio-vasculaires - Google Patents

Aryl-imidazolines et aryl-imidazoles utiles en tant qu'agents agonistes adrenergiques alpha-2 n'entrainant pas d'effets secondaires cardio-vasculaires Download PDF

Info

Publication number
CA2220517A1
CA2220517A1 CA002220517A CA2220517A CA2220517A1 CA 2220517 A1 CA2220517 A1 CA 2220517A1 CA 002220517 A CA002220517 A CA 002220517A CA 2220517 A CA2220517 A CA 2220517A CA 2220517 A1 CA2220517 A1 CA 2220517A1
Authority
CA
Canada
Prior art keywords
compound
formula
aryl
compounds
clonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002220517A
Other languages
English (en)
Inventor
Stephen A. Munk
James A. Burke
Ronald K. Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2220517A1 publication Critical patent/CA2220517A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Cette invention concerne des procédés permettant de traiter un mammifère dont l'état justifie un traitement d'agent agoniste alpha-2, et ce sans induire d'effets secondaires cardio-vasculaires. Ces procédés font usage de composé représenté par la formule (II) dans laquelle R1 est H, alkyle ayant de 1 à 4 atomes de carbone ou un atome d'halogène, X est O ou NH et A est H ou un groupe oxo, ce composé ne provoquant aucune réduction concomitante de la pression sanguine chez le mammifère traité.
CA002220517A 1995-05-12 1996-05-09 Aryl-imidazolines et aryl-imidazoles utiles en tant qu'agents agonistes adrenergiques alpha-2 n'entrainant pas d'effets secondaires cardio-vasculaires Abandoned CA2220517A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44003095A 1995-05-12 1995-05-12
US08/440,030 1995-05-12

Publications (1)

Publication Number Publication Date
CA2220517A1 true CA2220517A1 (fr) 1996-11-14

Family

ID=23747133

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002220517A Abandoned CA2220517A1 (fr) 1995-05-12 1996-05-09 Aryl-imidazolines et aryl-imidazoles utiles en tant qu'agents agonistes adrenergiques alpha-2 n'entrainant pas d'effets secondaires cardio-vasculaires

Country Status (5)

Country Link
EP (1) EP0828491A1 (fr)
JP (1) JPH11505224A (fr)
AU (1) AU715350B2 (fr)
CA (1) CA2220517A1 (fr)
WO (1) WO1996035424A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413576A3 (fr) * 1997-12-04 2004-09-01 Allergan, Inc. Dérivés d'imidazoles substituées et leur utilisation en tant qu'agonistes des récepteurs adrénergiques alpha 2B ou 2B/2C
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
JP3360073B2 (ja) * 2001-02-22 2002-12-24 花王株式会社 飲 料
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US8426454B2 (en) * 2007-08-15 2013-04-23 Allergan, Inc. Therapeutic compounds
WO2009023757A1 (fr) * 2007-08-15 2009-02-19 Allergan, Inc. Composés thérapeutiques
US8815861B2 (en) * 2011-07-25 2014-08-26 Allergan, Inc. N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
ES2160700T3 (es) * 1994-01-24 2001-11-16 Allergan Sales Inc Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a.

Also Published As

Publication number Publication date
AU5678596A (en) 1996-11-29
AU715350B2 (en) 2000-01-20
WO1996035424A1 (fr) 1996-11-14
EP0828491A1 (fr) 1998-03-18
JPH11505224A (ja) 1999-05-18

Similar Documents

Publication Publication Date Title
WO2005087750A1 (fr) Modulateurs de canaux ioniques
US6087361A (en) Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects
US5236943A (en) Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia
US5180721A (en) Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
JP2011256195A (ja) 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
EP0399791A1 (fr) Combinaisons d'agonistes et d'antagonistes alpha-adrénergiques sélectifs pour diminuer la pression intra-oculaire
US20220233505A1 (en) Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
CA2724293A1 (fr) Quinolynylmethylimidizoles en tant qu'agents therapeutiques
EP2716302B1 (fr) Agent prophylactique ou thérapeutique pour la douleur neuropathique associée au syndrome de guillain-barré
CA2220517A1 (fr) Aryl-imidazolines et aryl-imidazoles utiles en tant qu'agents agonistes adrenergiques alpha-2 n'entrainant pas d'effets secondaires cardio-vasculaires
AU2005222398A1 (en) Ion channel modulators
AU744018B2 (en) Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
US20060293359A1 (en) Methods and compositions for the treatment of diabetes
US20170172983A1 (en) Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
Venkataraman The imidazoline preferring receptors
GB2240476A (en) Use of 5HT-3 antagonist for preventing or reducing dependence

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead